Not every patient with ADHD can or should take a stimulant, and the non-stimulant options had been limited for years. Qelbree (viloxazine) broadened that shortlist.
Viloxazine is a selective norepinephrine reuptake inhibitor that improves attention and impulse control without the controlled-substance status or abuse potential of stimulants. The once-daily extended-release capsule is approved for ADHD in patients 6 years and older, including adults.
Qelbree remains marketed as a non-controlled alternative with no generic competition, and its label was expanded from pediatric to adult use after initial approval. It is a direct comparator to atomoxetine and a useful reference point for non-stimulant ADHD development.
